On February 11, in accordance with the relevant provisions of the Drug Administration Law, the State Food and Drug Administration conducted emergency review and approval in accordance with the special drug approval procedures, and conditionally approved the import registration of Pfizer's new coronavirus treatment drug Paxlovid.